Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
BörsenkürzelCAI
Name des UnternehmensCaris Life Sciences Inc
IPO-datumJun 18, 2025
Gegründet am2020
CEOMr. David Dean Halbert
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeJun 18
Addresse750 West John Carpenter Freeway
StadtIRVING
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl75039
Telefon18667718946
Websitehttps://www.carislifesciences.com/
BörsenkürzelCAI
IPO-datumJun 18, 2025
Gegründet am2020
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten